Sweden · Delayed Price · Currency is SEK ExpreS2ion Biotech Holding AB Earnings Call Transcripts
Fiscal Year 2026
-
Q2 2026 saw strong clinical progress for ES2B-C001, robust grant-driven financials, and a strengthened cash position following a rights issue. Phase I remains on track for end-2026 readout, with phase II planned for H2 2027 and ongoing partnering efforts supported by positive industry trends.
-
Q1 saw strong clinical and financial progress, with ES2B-C001 showing positive safety and immunogenicity, operating income up 132% year-over-year, and liquidity boosted by a rights issue. Multiple milestones are expected in oncology and infectious disease programs over the next year.
-
A novel anti-HER2 breast cancer vaccine shows promising preclinical and early clinical results, with durable antibody responses and no safety concerns so far. Over the next 12–18 months, further data will guide phase II plans, leveraging a validated protein platform and strategic partnerships.
Fiscal Year 2025
-
Q4 and full year 2025 saw strong clinical and financial progress, with income up 56% year-on-year and improved cost discipline. Key pipeline assets advanced, notably in oncology and infectious diseases, supported by grant funding and strategic partnerships.
-
Q3 saw strong execution with increased income, improved net loss, and expanded global partnerships, including a major malaria vaccine license. Cash runway extends into Q2 2026, with key clinical and partnership milestones expected over the next 18 months.
-
A novel HER2-targeted therapeutic vaccine is advancing through phase I trials, showing promising immune responses and potential to address high unmet needs in breast cancer. The therapy targets a large, growing market and is supported by a strong pipeline, recent partnerships, and a solid financial position.
-
A novel immunotherapy targeting all HER2 domains in breast cancer shows strong preclinical and early clinical results, with phase I data progressing and broader market expansion planned. Strategic partnerships and prudent financial management support a EUR 5 billion+ addressable market.
-
A novel immunotherapy targeting all four HER2 domains in breast cancer is showing promising preclinical and early clinical results, with significant market potential and a strategy focused on out-licensing after Phase I/II. Key data readouts and partnership milestones are expected through 2026.
-
Strong pipeline progress with the breast cancer vaccine trial expanding and new partnerships in malaria and influenza. H1 2025 income rose 61% year-over-year, with a SEK 49 million cash position providing runway through Q1 2026. Key data readouts expected in 2026.
-
Q1 saw a 90% rise in operating income and 44% growth in net sales, with a reduced net loss and strong cash position. ESGBC001 phase I trial is advancing with protocol amendments, while infectious disease programs progress through grant funding and partnerships.
Fiscal Year 2024
-
Q4 2024 saw a 5% drop in operating income and a SEK 16 million net loss, but year-end cash rose to SEK 82 million. Key milestones included CTA approval for the breast cancer vaccine, a major warrant subscription, and ongoing negotiations with the Serum Institute for malaria vaccines.
-
A novel HER2-targeting breast cancer vaccine is nearing phase I trials, supported by strong preclinical data and a robust leadership team. Strategic partnerships, including with Serum Institute of India, and ongoing funding initiatives position the company for significant growth in a €27 billion market.
-
A novel HER2-targeted breast cancer vaccine is advancing to phase I trials in early 2025, backed by strong preclinical results and validated technology. Expansion to other cancer indications and strategic partnerships, including with Serum Institute of India, are underway.
-
Q3 saw a narrowed net loss and reduced costs, with SEK 76 million in cash and a successful rights issue. Key milestones include a pending phase 1 trial for the breast cancer vaccine, a term sheet with Serum Institute of India, and progress in grant-funded projects.
-
A novel breast cancer vaccine, ES2B-C001, is advancing toward phase I trials, leveraging a clinically validated platform and strong preclinical results. The therapy targets HER2-positive cancers, aims to overcome resistance, and is positioned for premium pricing.
-
H1 2024 saw improved financials with a net profit in Q2, boosted by a SEK 22.5 million dividend and a SEK 30 million rights issue. The lead breast cancer vaccine candidate is on track for a phase I trial in Q1 2025, with funding dependent on warrant exercises.
-
A validated protein expression platform underpins a focused vaccine pipeline, led by a HER2+ breast cancer vaccine nearing clinical trials and supported by AI-driven antigen design. A SEK 60 million rights issue is underway to fund clinical development, with initial human data targeted for early 2026.